Multimodality therapeutic outcomes In anaplastic thyroid carcinoma: Improved survival in subgroups of patients with localized primary tumors

被引：88

作者：

Ito, Ken-ichi ^{[1
]}

Hanamura, Toru ^{[1
]}

Murayama, Koichi ^{[1
]}

Okada, Toshihiro ^{[1
]}

Watanabe, Takayuki ^{[1
]}

Harada, Michihiko ^{[1
]}

Ito, Tokiko ^{[1
]}

Koyama, Hiroshi ^{[1
]}

Kanai, Toshiharu ^{[1
]}

Maeno, Kazuma ^{[1
]}

Mochizuki, Yasuhiro ^{[1
]}

Amano, Jun ^{[2
]}

机构：

[1] Shinshu Univ, Sch Med, Div Breast & Endocrine Surg, Matsumoto, Nagano 390, Japan

[2] Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano 390, Japan

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2012年 / 34卷 / 02期

关键词：

anaplastic thyroid carcinoma; surgical treatment; chemotherapy; radiation; multimodality approach; DOXORUBICIN PLUS CISPLATIN; PROGNOSTIC-FACTORS; HYPERFRACTIONATED RADIOTHERAPY; CELL-CARCINOMA; CANCER; SURGERY; GIANT; CHEMOTHERAPY; MANAGEMENT; TRIAL;

D O I：

10.1002/hed.21721

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Background The aim of the present study was to investigate the role of a multimodality treatment for anaplastic thyroid carcinoma (ATC). Methods. Clinical data of 40 consecutive patients treated between 1985 and 2009 were retrospectively analyzed. Results. The median survival time (MST) stratified by clinical stage was 6.0 months for stage IVB and 4.2 months for stage IVC. When the stage IVB patients were classified into 2 groups (IVB-a and IVB-b) in accord with the extent of involvement of the tumor, the MST of the patients with IVB-a (9.6 months) was significantly longer than that of patients with IVB-b (4.0 months) (p<.05). The MST of the patients treated with surgery followed by radiation and chemotherapy (13.7 months) tended to be longer compared with the patients treated with 2 or fewer modalities. Conclusion. The patients with a less-invasive primary tumor may gain a survival benefit from aggressive multimodality therapeutic approaches. (C) 2011 Wiley Periodicals, Inc. Head Neck 34: 230-237, 2012

引用

页码：230 / 237

页数：8

共 48 条

[1]

Ain KB, 1999, SEMIN SURG ONCOL, V16, P64, DOI 10.1002/(SICI)1098-2388(199901/02)16:1<64::AID-SSU10>3.3.CO

[2]

2-L

[3] Anaplastic thyroid carcinoma: Behavior, biology, and therapeutic approaches [J].

Ain, KB .

THYROID, 1998, 8 (08) :715-726

[4] Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion [J].

Ain, KB ;

Egorin, MJ ;

DeSimone, PA .

THYROID, 2000, 10 (07) :587-594

[5] Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches [J].

Are, C ;

Shaha, AR .

ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (04) :453-464

[6]

Asakawa H, 1997, ANTICANCER RES, V17, P2757

[7] Effect of primary treatment on survival in anaplastic thyroid carcinoma [J].

Besic, N ;

Auersperg, M ;

Us-Krasovec, M ;

Golouh, R ;

Frkovic-Grazio, S ;

Vodnik, A .

EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (03) :260-264

[8] Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy [J].

De Crevoisier, R ;

Baudin, E ;

Bachelot, A ;

Leboulleux, S ;

Travagli, JP ;

Caillou, B ;

Schlumberger, M .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04) :1137-1143

[9]

DEMETER JG, 1991, SURGERY, V110, P956

[10]

Gilliland FD, 1997, CANCER-AM CANCER SOC, V79, P564, DOI 10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO

← 1 2 3 4 5 →